Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 5 | 2025 | 137 | 0.890 |
Why?
|
| Rituximab | 2 | 2021 | 164 | 0.800 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 569 | 0.760 |
Why?
|
| Malawi | 9 | 2025 | 423 | 0.740 |
Why?
|
| Wilms Tumor | 1 | 2023 | 119 | 0.740 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.710 |
Why?
|
| Anaphylaxis | 1 | 2021 | 86 | 0.640 |
Why?
|
| Immunologic Factors | 1 | 2021 | 184 | 0.640 |
Why?
|
| Neutropenia | 1 | 2021 | 201 | 0.630 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 463 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1334 | 0.580 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2017 | 14 | 0.560 |
Why?
|
| Rotavirus Vaccines | 1 | 2015 | 73 | 0.470 |
Why?
|
| Rotavirus Infections | 1 | 2015 | 357 | 0.390 |
Why?
|
| Rotavirus | 1 | 2015 | 502 | 0.380 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 358 | 0.380 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 52 | 0.370 |
Why?
|
| Norovirus | 1 | 2015 | 347 | 0.370 |
Why?
|
| HIV Infections | 5 | 2023 | 2066 | 0.350 |
Why?
|
| Encephalitis | 2 | 2023 | 121 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 809 | 0.340 |
Why?
|
| Child | 13 | 2025 | 25712 | 0.290 |
Why?
|
| Infant | 8 | 2025 | 13135 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1354 | 0.260 |
Why?
|
| Child, Preschool | 9 | 2025 | 14776 | 0.250 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.240 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 103 | 0.240 |
Why?
|
| Odds Ratio | 2 | 2021 | 1337 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 197 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 150 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.200 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17456 | 0.200 |
Why?
|
| Methotrexate | 1 | 2025 | 355 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2025 | 376 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2025 | 325 | 0.190 |
Why?
|
| Adolescent | 9 | 2025 | 20517 | 0.190 |
Why?
|
| Nephrectomy | 1 | 2023 | 181 | 0.180 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.180 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 125 | 0.170 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 43 | 0.170 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 36 | 0.170 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 52 | 0.170 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 50 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1482 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 148 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1315 | 0.160 |
Why?
|
| Humans | 16 | 2025 | 133849 | 0.150 |
Why?
|
| Anemia | 1 | 2023 | 350 | 0.150 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1386 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1314 | 0.150 |
Why?
|
| Hospitals | 2 | 2025 | 429 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 214 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 550 | 0.140 |
Why?
|
| Lymphoma | 1 | 2021 | 335 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 392 | 0.130 |
Why?
|
| Male | 10 | 2025 | 65815 | 0.130 |
Why?
|
| Bolivia | 1 | 2015 | 15 | 0.130 |
Why?
|
| Female | 10 | 2025 | 71584 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 239 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 408 | 0.110 |
Why?
|
| Prevalence | 2 | 2025 | 2654 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 240 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 2515 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1396 | 0.100 |
Why?
|
| Gastroenteritis | 1 | 2015 | 365 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 3063 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1631 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2021 | 5173 | 0.090 |
Why?
|
| Time Factors | 1 | 2021 | 6584 | 0.080 |
Why?
|
| Neoplasms | 1 | 2025 | 3025 | 0.080 |
Why?
|
| Genotype | 1 | 2015 | 2807 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 1204 | 0.080 |
Why?
|
| Young Adult | 1 | 2021 | 9885 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5505 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2025 | 48 | 0.060 |
Why?
|
| Blood Culture | 1 | 2025 | 34 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2025 | 73 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2025 | 181 | 0.050 |
Why?
|
| Tanzania | 1 | 2023 | 73 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 827 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8576 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6655 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 1467 | 0.050 |
Why?
|
| Bacteria | 1 | 2025 | 534 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 638 | 0.040 |
Why?
|
| Survival Rate | 1 | 2025 | 2207 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 31 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 535 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2019 | 453 | 0.030 |
Why?
|
| Adult | 3 | 2023 | 31925 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 5070 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3738 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1884 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 4532 | 0.020 |
Why?
|
| United States | 1 | 2023 | 11682 | 0.020 |
Why?
|